

Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/N4571358101EN.html>

Date: September 2020

Pages: 49

Price: US\$ 125.00 (Single User License)

ID: N4571358101EN

Abstracts

Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company has two marketed products - Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor which is marketed under the brand name JUXTAPID in the US for treating homozygous familial hypercholesterolemia (HoFH) in adult patients; and Metreleptin, a recombinant analog of human leptin which is marketed under the brand name MYALEPT in the US for treating congenital or acquired generalized lipodystrophy (GL) patients. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc Key Recent Developments

Jun 12,2020: Novelion Therapeutics provides update on liquidation and claims process

Nov 21,2019: Novelion Therapeutics provides updates on voluntary liquidation and other matters

Sep 25,2019: Novelion Therapeutics announces completion of Aegerion transaction and

departure of certain directors and officers

Sep 11,2019: Novelion Therapeutics announces US court confirmation of Aegerion bankruptcy case, update on Nasdaq delisting and date of annual general meeting of shareholders

Aug 30,2019: Novelion Therapeutics provides update regarding delisting from Nasdaq and Aegerion Bankruptcy Case

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Novelion Therapeutics Inc - Key Facts
Novelion Therapeutics Inc - Key Employees
Novelion Therapeutics Inc - Key Employee Biographies
Novelion Therapeutics Inc - Major Products and Services
Novelion Therapeutics Inc - History
Novelion Therapeutics Inc - Company Statement
Novelion Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Novelion Therapeutics Inc - Business Description
Product Category: Lomitapide
Overview
Performance
Product Category: Metreleptin
Overview
Performance
Geographical Segment: Brazil
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other Foreign countries
Performance
Geographical Segment: The US
Performance
Novelion Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Novelion Therapeutics Inc - Strengths
Novelion Therapeutics Inc - Weaknesses
Novelion Therapeutics Inc - Opportunities
Novelion Therapeutics Inc - Threats
Novelion Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Novelion Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 12, 2020: Novelion Therapeutics provides update on liquidation and claims process

Nov 21, 2019: Novelion Therapeutics provides updates on voluntary liquidation and other matters

Sep 25, 2019: Novelion Therapeutics announces completion of Aegerion transaction and departure of certain directors and officers

Sep 11, 2019: Novelion Therapeutics announces US court confirmation of Aegerion bankruptcy case, update on Nasdaq delisting and date of annual general meeting of shareholders

Aug 30, 2019: Novelion Therapeutics provides update regarding delisting from Nasdaq and Aegerion Bankruptcy Case

Jun 24, 2019: Novelion Therapeutics responds to Whitefort Capital Petition

May 07, 2019: Novelion Therapeutics reports first quarter 2019 financial results

Mar 14, 2019: Novelion Therapeutics reports fourth quarter and full year 2018 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

[About GlobalData](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Novelion Therapeutics Inc, Key Facts
Novelion Therapeutics Inc, Key Employees
Novelion Therapeutics Inc, Key Employee Biographies
Novelion Therapeutics Inc, Major Products and Services
Novelion Therapeutics Inc, History
Novelion Therapeutics Inc, Other Locations
Novelion Therapeutics Inc, Subsidiaries
Novelion Therapeutics Inc, Key Competitors
Novelion Therapeutics Inc, Ratios based on current share price
Novelion Therapeutics Inc, Annual Ratios
Novelion Therapeutics Inc, Annual Ratios (Cont...1)
Novelion Therapeutics Inc, Interim Ratios
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novelion Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Novelion Therapeutics Inc, Performance Chart (2014 - 2018)

Novelion Therapeutics Inc, Ratio Charts

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Sanofi

Eli Lilly and Co

Amgen Inc

RegenxBio Inc

Alnylam Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

NeuroBo Pharmaceuticals Inc

The Medicines Co

Akcea Therapeutics Inc

I would like to order

Product name: Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/N4571358101EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N4571358101EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970